Results 91 to 100 of about 58,715 (237)

Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure [PDF]

, 2015
AIM: Portal hypertension is a common complication of liver cirrhosis and significantly increases mortality and morbidity. Previous reports have suggested that the compound thalidomide attenuates portal hypertension (PHT).
Korshunov, Vyacheslav A., Maluccio, Mary A., Skill, Nicholas J., Theodorakis, Nicholas G., Wang, Yining N.   +4 more
core   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Thalidomide for the treatment of gastrointestinal bleeding due to angiodysplasia in a patient with Glanzmann’s thrombasthenia

Hematology Reports, 2017
Angiodysplasia is a frequent cause of persistent gastrointestinal (GI) hemorrhage in elderly patients. Although GI bleeding isn’t the most common manifestation in patients with bleeding disorders, when present, it represents a challenging complication ...
Bruno K.L. Duarte, Silvia M. de Souza, Carolina Costa-Lima, Samuel S. Medina, Margareth C. Ozelo   +4 more
doaj   +1 more source

An unusual case of multiple myeloma [PDF]

, 2013
The case concerns the unusual presentation of a non-secretory multiple myeloma with diarrhoea secondary to large bowel infiltration. In December 2009, a 74-year-old lady presented to hospital and complained of a two year history of intermittent ...
Delicata, Julian, Farrugia, Daniel
core  

Biochemical bone biomarkers in plasma cell dyscrasias

British Journal of Haematology, EarlyView.
Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador, Rohit Vijjhalwar, Muhammad Kassim Javaid, Claire M. Edwards, Karthik Ramasamy   +4 more
wiley   +1 more source

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study

Cancer Reports
Background Thalidomide‐containing regimens cause adverse events (AEs) that may require a reduction in treatment intensity or even treatment discontinuation in patients with multiple myeloma. As thalidomide toxicity is dose‐dependent, identifying the most
Po‐Wei Liao, Hsueh‐Ju Lu, Tsung‐Chih Chen, Hsin‐Chen Lin, Yu‐Hsuan Shih, Chieh‐Lin Jerry Teng   +5 more
doaj   +1 more source

Transcriptomic changes in mouse embryonic stem cells exposed to thalidomide during spontaneous differentiation

Data in Brief, 2015
Thalidomide is a potent developmental toxicant that induces a range of birth defects, notably severe limb malformations. To unravel the molecular mechanisms underpinning the teratogenic effects of thalidomide, we used microarrays to study transcriptomic ...
Xiugong Gao, Robert L. Sprando, Jeffrey J. Yourick   +2 more
doaj   +1 more source

Codes of Ethics in Research and Experimentation in Man [PDF]

, 1973
Professor Liley\u27s most notable contribution to medicine was the introduction of intrauterine fetal blood transfusion in the management of Rh sensitization. His work has had worldwide recognition.
Liley, A. W.
core   +1 more source

Thalidomide-induced Teratogenesis : History and Mechanisms [PDF]

, 2015
Peer reviewedPublisher ...
Arlen RR, Hamanishi C, Jonsson NA, Lenz W, Lenz W, Livingstone G, McBride W, Ng SS, Packard DS, Ruffing L, Schmidt M, Smith RL, Soules BJ, UK Government Report   +13 more
core   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, EarlyView.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source